Uso de altas doses de aspirina no tratamento da Doença de Kawasaki: revisão integrativa.

Abstract

Kawasaki disease is a vasculitis that affects mainly pediatric patients, with a greater incidence in the Asian continent, but present at a global level, with the most common and feared complication being the formation of coronary aneurysms, a sequel that confers great morbidity on the affected patients. can be avoided by an early diagnosis and initiation of the correct treatment. recommended by the American Heart Association, treatment includes specific intravenous immunoglobulin, in addition to aspirin in high doses. The aim of this study was to evaluate whether the use of aspirin in high doses really has clinical relevance in the treatment of Kawasaki Disease. As for the methodological design, an integrative review was performed using the following databases as the research source: Latin American and Caribbean Literature in Health Sciences (LILACS), International Medical Database Published - Service of the US National Library of Medicine (PubMed) and Scientific Electronic Library Online (Scielo). We used the descriptors Kawasaki disease, aspirin dose, ASA dose, coronary aneurism, Kawasaki disease and aspirin dose, in addition to the Boolean operator AND. The full-text articles available, free or paid, published in the last twenty years were selected. Eight papers were selected at the end and studies that did not go into the treatment of the disease in question were excluded. After analyzing the included studies, it was observed that aspirin in high doses did not contribute to the prevention of coronary aneurysms in the short and medium term, besides not reducing the duration of the fever, the resistance to the treatment or the length of hospital stay. Adding to this is the fact that high doses of the drug can cause a number of side effects, such as anemia, gastrointestinal and neurological disorders, and delayed normalization of blood inflammatory markers. Thus, it is suggested that it is necessary to review the prescription of high doses of aspirin as a mandatory practice in the treatment of Kawasaki disease, as well as to promote a standardization of the treatment protocols of the disease, which still present many divergences between the different institutions, with supported by new studies on the subject.